Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

12.9%

13 terminated out of 101 trials

Success Rate

75.5%

-11.0% vs benchmark

Late-Stage Pipeline

9%

9 trials in Phase 3/4

Results Transparency

20%

8 of 40 completed with results

Key Signals

8 with results75% success13 terminated

Data Visualizations

Phase Distribution

69Total
Not Applicable (13)
Early P 1 (3)
P 1 (21)
P 2 (23)
P 3 (6)
P 4 (3)

Trial Status

Completed40
Unknown16
Recruiting16
Terminated13
Active Not Recruiting8
Withdrawn5

Trial Success Rate

75.5%

Benchmark: 86.5%

Based on 40 completed trials

Clinical Trials (101)

Showing 20 of 20 trials
NCT04483778Phase 1Active Not Recruiting

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT01109394Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT03050268Recruiting

Familial Investigations of Childhood Cancer Predisposition

NCT04959097RecruitingPrimary

Retinoblastoma Patient Clinical Database and Tissue Repository

NCT07530458Not Yet RecruitingPrimary

Retinoblastoma Consolidation in Egyptians

NCT03016156Not ApplicableTerminatedPrimary

Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

NCT06679634Phase 2RecruitingPrimary

Retinoblastoma Phase II Expanded Access Clinical Trial

NCT06725173Recruiting

Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.

NCT04425434RecruitingPrimary

Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma

NCT00639301Active Not RecruitingPrimary

Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life

NCT02870907Phase 2Active Not RecruitingPrimary

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

NCT03267459RecruitingPrimary

Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?

NCT05650749Phase 1Recruiting

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

NCT06227962Enrolling By InvitationPrimary

Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors

NCT04681417Phase 2RecruitingPrimary

Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

NCT02866136Phase 2Active Not RecruitingPrimary

Conservative Treatments of Retinoblastoma

NCT03618381Phase 1Active Not Recruiting

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT04344652Not ApplicableWithdrawnPrimary

Photoscreening for Retinoblastoma

NCT03932786RecruitingPrimary

Studying Health Outcomes After Treatment in Patients With Retinoblastoma

NCT00186888Phase 3CompletedPrimary

Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma

Scroll to load more

Research Network

Activity Timeline